Protein kinase D activation stimulates the transcription of the insulin receptor gene

Molecular and Cellular Endocrinology

Volumn 330, Issue 1-2, 2010, Pages 25-32

  Zhang, Hao ^a   Kong, Wei Jia ^a   Shan, Yong Qiang ^a   Song, Dan Qing ^a   Li, Yi ^a   Wang, Yue Ming ^a   You, Xue Fu ^a   Jiang, Jian Dong ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

Author keywords

Berberine; Gene expression; Insulin receptor; Protein kinase D

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; BERBERINE; INSULIN RECEPTOR; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; PROTEIN KINASE C DELTA; PROTEIN KINASE C EPSILON; PROTEIN KINASE C ETA; PROTEIN KINASE C GAMMA; PROTEIN KINASE C IOTA; PROTEIN KINASE C LAMBDA; PROTEIN KINASE C MU; PROTEIN KINASE C THETA; PROTEIN KINASE C ZETA; PROTEIN KINASE D; PROTEIN KINASE D1; PROTEIN KINASE D2; PROTEIN KINASE D3; RUBOXISTAURIN; SERINE; UNCLASSIFIED DRUG;

ARTICLE; AUTOPHOSPHORYLATION; CATALYSIS; CELL MEMBRANE; CONTROLLED STUDY; CYTOSOL; DOSE RESPONSE; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; GENE SILENCING; GLUCOSE INTAKE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSCRIPTION REGULATION; UPREGULATION;

BERBERINE; CARBAZOLES; ENZYME ACTIVATION; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HEP G2 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; ISOENZYMES; OLIGOMYCINS; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; RECEPTOR, INSULIN; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 77957667482     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2010.07.022     Document Type: Article

References (45)

1. Araki E., Murakami T., Shirotani T., Kanai F., Shinohara Y., Shimada F., Mori M., Shichiri M., Ebina Y. A cluster of four Sp1 binding sites required for efficient expression of the human insulin receptor gene. J. Biol. Chem. 1991, 266:3944-3948.
2. Avkiran M., Rowland A.J., Cuello F., Haworth R.S. Protein kinase D in the cardiovascular system: emerging roles in health and disease. Circ. Res. 2008, 102:157-163.
3. Bain J., Plater L., Elliott M., Shpiro N., Hastie C.J., McLauchlan H., Klevernic I., Arthur J.S., Alessi D.R., Cohen P. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 2007, 408:297-315.
4. Chen J., Lu G., Wang Q.J. Protein kinase C-independent effects of protein kinase D3 in glucose transport in L6 myotubes. Mol. Pharmacol. 2005, 67:152-162.
5. Ebina Y., Ellis L., Jarnagin K., Edery M., Graf L., Clauser E., Ou J.H., Masiarz F., Kan Y.W., Goldfine I.D., Roth R.A., Rutter W.J. The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signaling. Cell 1985, 40:747-758.
6. Foti D., Iuliano R., Chiefari E., Brunetti A. A nucleoprotein complex containing Sp1, C/EBP beta, and HMGI-Y controls human insulin receptor gene transcription. Mol. Cell. Biol. 2003, 23:2720-2732.
7. Goldstein B.J. Protein-tyrosine phosphatases: emerging targets for therapeutic intervention in type 2 diabetes and related states of insulin resistance. J. Clin. Endocrinol. Metab. 2002, 87:2474-2480.
8. Gonzalez-Sanchez J.L., Serrano-Rios M. Molecular basis of insulin action. Drug News Perspect. 2007, 20:527-531.
9. Gschwendt M., Dieterich S., Rennecke J., Kittstein W., Mueller H.J., Johannes F.J. Inhibition of protein kinase C μ by various inhibitors. Differentiation from protein kinase c isoenzymes. FEBS Lett. 1996, 392:77-80.
10. Hayashi A., Seki N., Hattori A., Kozuma S., Saito T. PKCν, a new member of the protein kinase C family, composes a fourth subfamily with PKCμ. Biochim. Biophys. Acta 1999, 1450:99-106.
11. Hsu S.L., Chou Y.H., Yin S.C., Liu J.Y. Differential effects of phorbol ester on growth and protein kinase C isoenzyme regulation in human hepatoma Hep3B cells. Biochem. J. 1998, 333:57-64.
12. Iwanishi M., Haruta T., Takata Y., Ishibashi O., Sasaoka T., Egawa K., Imamura T., Naitou K., Itazu T., Kobayashi M. A mutation (Trp1193→Leu1193) in the tyrosine kinase domain of the insulin receptor associated with type A syndrome of insulin resistance. Diabetologia 1993, 36:414-422.
13. Jirousek M.R., Gillig J.R., Gonzalez C.M., Heath W.F., McDonald J.H., Neel D.A., Rito C.J., Singh U., Stramm L.E., Melikian-Badalian A., Baevsky M., Ballas L.M., Hall S.E., Winneroski L.L., Faul M.M. (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase Cβ. J. Med. Chem. 1996, 39:2664-2671.
14. Johannes F.J., Prestle J., Eis S., Oberhagemann P., Pfizenmaier K. PKCμ is a novel, atypical member of the protein kinase C family. J. Biol. Chem. 1994, 269:6140-6148.
15. Kadowaki T., Kadowaki H., Taylor S.I. A nonsense mutation causing decreased levels of insulin receptor mRNA: detection by a simplified technique for direct sequencing of genomic DNA amplified by the polymerase chain reaction. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:658-662.
16. Kido Y., Nakae J., Accili D. Clinical review 125: the insulin receptor and its cellular targets. J. Clin. Endocrinol. Metab. 2001, 86:972-979.
17. Kong W., Wei J., Abidi P., Lin M., Inaba S., Li C., Wang Y.L., Wang Z., Si S., Pan H., Wang S., Wu J.D., Wang Y., Li Z.R., Liu J., Jiang J.D. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat. Med. 2004, 10:1344-1351.
18. Kong W.J., Zhang H., Song D.Q., Xue R., Zhao W., Wei J., Wang Y.M., Shan N., Zhou Z.X., Yang P., You X.F., Li Z.R., Si S.Y., Zhao L.X., Pan H.N., Jiang J.D. Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression. Metabolism 2009, 58:109-119.
19. Krook A., Stratton I.M., O'Rahilly S. Rapid and simultaneous detection of multiple mutations by pooled and multiplex single nucleotide primer extension: application to the study of insulin-responsive glucose transporter and insulin receptor mutations in non-insulin-dependent diabetes. Hum. Mol. Genet. 1992, 1:391-395.
20. Kusari J., Takata Y., Hatada E., Freidenberg G., Kolterman O., Olefsky J.M. Insulin resistance and diabetes due to different mutations in the tyrosine kinase domain of both insulin receptor gene alleles. J. Biol. Chem. 1991, 266:5260-5267.
21. Lee Y.S., Kim W.S., Kim K.H., Yoon M.J., Cho H.J., Shen Y., Ye J.M., Lee C.H., Oh W.K., Kim C.T., Hohnen-Behrens C., Gosby A., Kraegen E.W., James D.E., Kim J.B. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 2006, 55:2256-2264.
22. Luiken J.J., Vertommen D., Coort S.L., Habets D.D., El Hasnaoui M., Pelsers M.M., Viollet B., Bonen A., Hue L., Rider M.H., Glatz J.F. Identification of protein kinase D as a novel contraction-activated kinase linked to GLUT4-mediated glucose uptake, independent of AMPK. Cell Signal. 2008, 20:543-556.
23. Mamula P.W., Wong K.Y., Maddux B.A., McDonald A.R., Goldfine I.D. Sequence and analysis of promoter region of human insulin-receptor gene. Diabetes 1988, 37:1241-1246.
24. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science 2002, 298:1912-1934.
25. Martiny-Baron G., Kazanietz M.G., Mischak H., Blumberg P.M., Kochs G., Hug H., Marmé D., Schächtele C. Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976. J. Biol. Chem. 1993, 268:9194-9197.
26. Matthews S.A., Rozengurt E., Cantrell D. Characterization of serine 916 as an in vivo autophosphorylation site for protein kinase D/protein kinase Cμ. J. Biol. Chem. 1999, 274:26543-26549.
27. McKeon C., Moncada V., Pham T., Salvatore P., Kadowaki T., Accili D., Taylor S.I. Structural and functional analysis of the insulin receptor promoter. Mol. Endocrinol. 1990, 4:647-656.
28. Papazyan R., Doche M., Waldron R.T., Rozengurt E., Moyer M.P., Rey O. Protein kinase D isozymes activation and localization during mitosis. Exp. Cell. Res. 2008, 314:3057-3068.
29. Pollack I.F., Kawecki S. The effect of calphostin C, a potent photodependent protein kinase C inhibitor, on the proliferation of glioma cells in vitro. J. Neurooncol. 1997, 31:255-266.
30. Rozengurt E., Rey O., Waldron R.T. Protein kinase D signaling. J. Biol. Chem. 2005, 280:13205-13208.
31. Seino S., Seino M., Nishi S., Bell G.I. Structure of the human insulin receptor gene and characterization of its promoter. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:114-118.
32. Srivastava A.K., Mehdi M.Z. Insulin-mimetic and anti-diabetic effects of vanadium compounds. Diabet. Med. 2005, 22:2-13.
33. Steinberg S.F. Structural basis of protein kinase C isoform function. Physiol. Rev. 2008, 88:1341-1378.
34. Sturany S., Van Lint J., Muller F., Wilda M., Hameister H., Hocker M., Brey A., Gern U., Vandenheede J., Gress T., Adler G., Seufferlein T. Molecular cloning and characterization of the human protein kinase D2. A novel member of the protein kinase D family of serine threonine kinases. J. Biol. Chem. 2001, 276:3310-3318.
35. Sumara G., Formentini I., Collins S., Sumara I., Windak R., Bodenmiller B., Ramracheya R., Caille D., Jiang H., Platt K.A., Meda P., Aebersold R., Rorsman P., Ricci R. Regulation of PKD by the MAPK p38δ in insulin secretion and glucose homeostasis. Cell 2009, 136:235-248.
36. Valverde A.M., Sinnett-Smith J., Van Lint J., Rozengurt E. Molecular cloning and characterization of protein kinase D: a target for diacylglycerol and phorbol esters with a distinctive catalytic domain. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:8572-8576.
37. Van Lint J.V., Sinnett-Smith J., Rozengurt E. Expression and characterization of PKD, a phorbol ester and diacylglycerol-stimulated serine protein kinase. J. Biol. Chem. 1995, 270:1455-1461.
38. Waldron R.T., Rozengurt E. Protein kinase C phosphorylates protein kinase D activation loop Ser744 and Ser748 and releases autoinhibition by the pleckstrin homology domain. J. Biol. Chem. 2003, 278:154-163.
39. Wang Q.J. PKD at the crossroads of DAG and PKC signaling. Trends Pharmacol. Sci. 2006, 27:317-323.
40. Wang Y.X., Wang Y.P., Zhang H., Kong W.J., Li Y.H., Liu F., Gao R.M., Liu T., Jiang J.D., Song D.Q. Synthesis and biological evaluation of berberine analogues as novel up-regulators for both low-density-lipoprotein receptor and insulin receptor. Bioorg. Med. Chem. Lett. 2009, 19:6004-6008.
41. Wilkinson S.E., Parker P.J., Nixon J.S. Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C. Biochem. J. 1993, 294:335-337.
42. Yang C., Kazanietz M.G. Divergence and complexities in DAG signaling: looking beyond PKC. Trends Pharmacol. Sci. 2003, 24:602-608.
43. 2 but not tumor necrosis factor. J. Biol. Chem. 2005, 280:19036-19044.
44. Zhang H., Wei J., Xue R., Wu J.D., Zhao W., Wang Z.Z., Wang S.K., Zhou Z.X., Song D.Q., Wang Y.M., Pan H.N., Kong W.J., Jiang J.D. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism 2010, 59:285-292.
45. Zugaza J.L., Sinnett-Smith J., Van Lint J., Rozengurt E. Protein kinase D (PKD) activation in intact cells through a protein kinase C-dependent signal transduction pathway. EMBO J. 1996, 15:6220-6230.